Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in the Treatment of Cicatricial Alopecias
NCT07508488Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucravacitinib in central centrifugal cicatricial alopecia (CCCA), frontal fibrosing alopecia (FFA), sponsored by Icahn School of Medicine at Mount Sinai. Started May 2026; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
central centrifugal cicatricial alopecia (CCCA)frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on NCT07508488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508488.